PDF Format

Fukushima, Japan – ARCALIS, Inc. (Headquarters: Minamisoma City, Fukushima Prefecture; Representative Director, President and CEO: Satoshi Takamatsu, hereinafter “ARCALIS”) announces that it has entered into a Memorandum of Understanding (MOU) for comprehensive collaboration with the Fukushima Medical University (Location: Fukushima City, Fukushima Prefecture; Chairman: TAKENOSHITA Seiichi, hereinafter “Fukushima Medical University”) and the Fukushima Translational Research Foundation (Location: Fukushima City, Fukushima Prefecture; President: Shun-ichiro Iemura, hereinafter “TR Foundation”) to advance research, development, and manufacturing of mRNA pharmaceuticals and vaccines.

Under this MOU, ARCALIS will work with Fukushima Medical University and TR Foundation to jointly promote research and development of mRNA pharmaceuticals and vaccines—including vaccines for infectious diseases and cancer therapeutic vaccines—to implement the results of the Fukushima Pharmaceutical Industry Support Base Project (hereinafter “Fukushima Project”), led by the Translational Research Center at Fukushima Medical University, into practical application. Additionally, ARCALIS will collaborate with Fukushima Medical University and the TR Foundation to explore seed genes potentially applicable to mRNA pharmaceuticals and vaccines, utilizing the results of the Fukushima Project. Through these initiatives, the collaboration aims to accelerate the production and clinical trials of biopharmaceuticals including mRNA pharmaceuticals and vaccines in Fukushima Prefecture and across Japan, contributing to the development of a bio-industry in Japan.

Satoshi Takamatsu, Representative Director, President and CEO of ARCALIS, said “I am very pleased to conclude the MOU for a comprehensive collaboration with Fukushima Medical University and TR Foundation. With the conclusion of this MOU, ARCALIS will pursue joint research and development with Fukushima Medical University and TR Foundation for the practical application of mRNA pharmaceuticals and vaccines, and will work together to generate innovative therapeutics originating from Fukushima. ARCALIS will contribute to the realization of a healthy future for people around the world by providing high-quality, reliable services for the development and manufacture of mRNA pharmaceuticals and vaccines to a diverse range of customers, including academia, biotech companies, and pharmaceutical companies in Japan and overseas.”

About ARCALIS  https://corp.arcalis.co.jp/en/
ARCALIS is an mRNA vaccines and therapeutics contract development and manufacturing organization (“CDMO”), jointly established by Axcelead, Inc. (Representative Director, President and CEO, Nobuhiro Todokoro) and Arcturus Therapeutics, Inc. (NASDAQ: ARCT). ARCALIS aims to develop the world’s first mRNA vaccines and therapeutics CDMO business that promises a stable supply of high-quality mRNA medicines to all customers, including Arcturus, other pharmaceutical companies, biotech companies, and academic institutes worldwide. The new facility in the city of Minamisoma (Fukushima prefecture) is equipped with state-of-the-art manufacturing and quality control systems that meet the cGMP standards for pharmaceuticals.